Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

This update describes a Phase 3 clinical trial evaluating obinutuzumab for systemic lupus erythematosus, with study status currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Gazyva (obinutuzumab) (obinutuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: ACTIVE_NOT_RECRUITING